Aptorum Group Limited operates as a biopharmaceutical firm, primarily engaged in the identification, development, and commercialization of medicinal treatments. Its core therapeutic efforts are directed towards combating infectious diseases and various forms of cancer. The company's operations are bifurcated into two distinct divisions: Therapeutics and Non-Therapeutics. Aptorum boasts a diverse product pipeline, featuring several key candidates. In the field of oncology, SACT-1 is under development for neuroblastoma and other cancer types. For infectious diseases, SACT-COV19 is being advanced for coronavirus, while ALS-4 targets bacterial infections caused by Staphylococcus aureus, including antibiotic-resistant MRSA strains. ALS-1 is designed to address viral infections like influenza A, and ALS-2/3 focuses on gram-positive bacterial infections. Beyond these, the company is progressing NLS-1 for endometriosis, DLS-1+2 for non-small cell lung cancer (NSCLC) with specific mutations, DLS-3 as a small molecule for autoimmune conditions, and CLS-1 for obesity management. The non-therapeutic portfolio includes RPIDD, a molecular diagnostic tool for pathogens, and NativusWell DOI (NLS-2), a dietary supplement. Aptorum utilizes various innovative approaches for discovering new therapeutic assets, such as systematic screening of already approved drug molecules and employing microbiome-based research platforms, particularly for metabolic ailments. The company also explores therapeutic and diagnostic solutions across other fields, including neurology, gastroenterology, metabolic disorders, and women's health. Furthermore, Aptorum Group Limited also operates a medical clinic. Founded in 2010, Aptorum Group Limited maintains its corporate headquarters in London, United Kingdom.